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ABSTRACT 
 
A biochemical case study is reported on a 50-year old lady known to have breast cancer. The 
woman was treated by mastectomy and this was followed by unraveling brain metastases 
three years post-diagnosis of the cancer, which was treated by radiation and chemotherapy. 
Two months after ending her treatment, she exhibited acute changes in her mental status ma-
nifested by severe amnesia and fever. A generalized analytical and biochemical assessment 
revealed the presence of paraneoplastic limbic encephalitis. 
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INTRODUCTION  
AND BACKGROUND 
Paraneoplastic neurological syndromes 
(PNS) are regarded as remote offshoots of 
cancer that are not caused by invasion of 
the tumor or its metastases (Graus and Dal-
mau, 2007). Immunologic and biochemical 
factors implicated with the aforementioned 
are believed to be significant in the patho-
genesis of PNS because antibodies (hu-
moral) and T-cell mediated responses 
against nervous system antigens (onconeu-
ral) have been identified with several of 
those disorders (Graus and Dalmau, 2007; 
Aznar et al., 2007; Storstein and Vedeler, 
2007; Honnorat and Antoine, 2007).  
At the onset of the neurologic symp-
toms, most patients may have not yet been 
diagnosed with cancer (Graus and Dalmau, 
2007). On the other hand, in patients known 
to have established cancer, the presentation 
of a PNS condition may herald recurrence 
of a primary or secondary tumor (Graus and 
Dalmau, 2007). Rapid detection and imme-
diate treatment of the underlying tumor ap-
pear to offer the best chance of stabilizing 
the patient and thus preventing further neu-
rological deterioration (Aznar et al., 2007; 
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Storstein and Vedeler, 2007; Honnorat and 
Antoine, 2007). 
 
CASE REPORT ASSESSMENT 
A 50 year old lady known to have a his-
tory of cancer, and whose left breast tumor 
was treated by mastectomy, 3 years today, 
was diagnosed with brain metastasis, re-
cently discovered, and presented as right 
hemiplegia that was treated by 30 cycles of 
radiotherapy and chemotherapy. Biochemi-
cally speaking, she was under a treatment 
regimen of phenytoin, prednisone, proton 
pump inhibitors, lovenox, xeloda, nevalbin 
(Graus and Dalmau, 2007). 
Two months following the last course of 
radiotherapy, she was presented to the 
emergency room at Notre Dame de Se-
cours, Byblos, Lebanon, with an acute onset 
of mental changes, severe amnesia and ab-
normal face movements. 
On physical examination, she was con-
sidered as essentially stable hemodyna-
mically, besides having a fever of 39 °C. 
Confused spatially and temporally, her 
Glasgow score was roughly 13. In addition, 
she was having clonic movement of the 
right lip and eyelid, and despite the fact that 
her cranial nerves were normal, her old 
right side exhibited conspicuous weakness 
and hyperreflexia, where cutaneo-planter 
reflexes were in flexion, sensitivity and 
gait; however, her coordination was diffi-
cult to assess (Graus and Dalmau, 2007). 
The physical exam, furthermore, was nor-
mal with no cleared site for any infections. 
Technically, the biochemical ER differ-
ential diagnosis was the following accord-
ing to manifestations:  
• Hypoglycemia, 
• Encephalitis: infectious- metabolic-
neoplastic – radiation, 
• Meningitis vs. meningoencephalitis, 
• Cerebrovascular problems (hemorrhagic 
or ischemic), 
• Mass lesions like metastasis, 
• Subclinical status epilepticus, 
• Hypothyroidism, 
• Low vitamin B12 and 
• Infections. 
Furthermore, as initial management was 
undertaken for the aforementioned, the fol-
lowing were recognized: serum glucose was 
100 mg/dl; CT scan of the brain did elimi-
nate intracranial bleeding; EEG was nor-
mal; CSF analysis was insignificant; ECG 
and chest x-ray were normal; laboratory 
results were generally normal; and thyroid 
stimulating hormone (TSH) was relatively 
high with low free T3 and T4. Phenytoin 
level, in addition, was low, with low cal-
cium concentration (Graus and Dalmau, 
2007; Aznar et al., 2007; Storstein and Ve-
deler, 2007). 
Intravenous (IV) calcium and IV an-
tiepileptic drugs regimens ensued with scru-
tinized clinical observation. On the second 
day following admission, neurological reas-
sessment demonstrated the presence of dis-
orientation, severe amnesia (anterograde > 
retrograde), and no more clonic movement. 
Brain MRI was performed to show the 
presence of old metastasis lesion in the left 
temporo-parietal region with decreased se-
verity of the surrounding edema (by com-
parison with the last MRI done when brain 
metastasis has been diagnosed) (Figures 1, 
2 and 3). 
The patient started taking L-thyroxin, 
calcium, phenytoin, decadron and valproic 
acid. Few days after, she still was amnesic 
with wax and wane mental status but with 
no more fever or any abnormal jerks. They 
gave her the usually scheduled chemother-
apy (one course every 2 weeks). 
Two days after, she recurred to have fe-
ver of 38.5 – 39 °C, with no alarming sign 
of infections. CBCD revealed neutropenia 
and the diagnosis of neutropenic fever was 
taken further into consideration (Graus and 
Dalmau, 2007). Another CSF was exam-
ined for analysis, culture, Gram stain and 
PCR of herpes, and MRI of the brain was 
done (Figures 4 and 5) with a full coverage 
of the patient with broad spectrum antibiot-
ics (Targocid, amikin, tazocin) and zovirax.
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Figure 1: MRI showing the metastatic lesion with the surrounding edema 
 
 
Figure 2: MRI with Gadolinium 
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Figure 3: MRI with Gadolinium, continued 
 
 
 
 
Figure 4: MRI with Gadolinium, continued 
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Figure 5: MRI with Gadolinium, continued 
 
 
CSF tests were negative all over, and 
MRI showed the presence of hyper signal 
temporal lobe in the left side more than in 
the right one. The differential diagnosis 
changed at that point and it was directed 
toward the diseases (syndromes) causing 
hyper signal lesions on MRI of the brain, 
which were as follows:  
• Herpes encephalitis: there was elimina-
tion by negative PCR and CSF tests; 
• Infiltrating neoplasm: there was no 
mass lesion other than the old metasta-
sis away from the new one; 
• Ischemia: which indicated against this 
diagnosis the absence of specific vascu-
lar distribution; 
• Post-ictal lesion: the patient was asymp-
tomatic, clinically, and the EEG was 
normal; and 
• Limbic encephalitis was considered as 
the most probable case. 
 
The diagnosis of limbic encephalitis 
was based on the clinical assessment, risk 
factor (breast cancer), and the MRI lesion 
(Anderson and Barber, 2008; Graus and 
Saiz, 2008). The patient took solumedrol in 
high dose for 5 days, zovirax was stopped, 
and antibiotics were continued till the 14th 
day with clinical follow up on daily basis. 
Ten days after embarking on the diagnosis 
of limbic encephalitis, the patient was trans-
ferred home with stable mental status, mild 
amnesia, old right hemiplegia, and no more 
fever or jerks. On the other hand, WBC in-
creased to normal levels on the day of dis-
charge. Two weeks after, she was admitted 
at the clinic for follow up and she was 
manifesting the same status (Lucas-
Ramadan et al., 2008). 
 
DISCUSSION 
Paraneoplastic limbic encephalitis 
(PLE) is one of the rare PNS characterized 
by subacute onset (in days to a few months) 
of the short-term memory loss, seizures, 
confusion, and psychiatric symptoms, sug-
gesting involvement of the limbic system 
(Graus and Dalmau, 2007). Hypothalamic 
dysfunction may occur with somnolence, 
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hyperthermia, and endocrine abnormalities. 
Also, it is part of paraneoplastic encepha-
lomyelitis, with involvement of other areas 
outside the limbic system and brainstem. 
Selective impairment of reception 
memory is the hallmark of the disease but 
may not be evident in patients presented 
with severe confusion or multiple seizures 
(Graus and Dalmau, 2007; Lucas-Ramadan 
et al., 2008). More than half of the patients 
admitted with limbic encephalitis may have 
an underlying neoplasm. Lung tumor may 
occur in 50-60 % (usually SCLC), testicular 
germ cell tumor in 20 %, and others may 
include breast cancer, similar to the afore-
mentioned case, thymoma, Hodgkin’s dis-
ease, and immature teratomas. 
Clinically, PLE is divided into several 
groups, the most important of which are the 
following:  
• Patients with anti-Hu antibodies and 
lung cancer (older, median age 62 years, 
female, smokers); 
• Patients with anti-Ma2 antibodies and 
testicular cancer (younger, median age 
34 years, male); and 
• Patients with no anti-neuronal antibod-
ies (40 % of cases). 
 
The diagnosis of limbic encephalitis is 
often difficult because there are no specific 
clinical markers and symptoms (Ghosh et 
al., 2007). MRI and CT scans have shown 
abnormalities in 65-80 % of patients con-
sisting of increased signal on T2-weighted 
and fluid-attenuated inversion-recovery im-
ages of one or both medical temporal lobes, 
hypothalamus, and brainstem. Co-registra-
tion of FDG-PET may further improve the 
sensitivity of imaging. 
Moreover, CSF examination is abnor-
mal in approximately 80 % of patients, 
showing transient mild lymphocytic pleocy-
tosis with elevated protein, IgG, or oligo-
clonal bands. The detection of paraneoplas-
tic antibodies may help establish diagnostic 
criteria and direct a tumor search that in-
cludes the lung, breasts, and testicles in the 
absence of paraneoplastic antibodies (Stor-
stein and Vedeler, 2007; Honnorat and An-
toine, 2007; Anderson and Barber, 2008). 
Antineuronal antibodies are also found 
in approximately 60 % of cases. The most 
frequent related paraneoplastic antibodies 
are: 
• Anti-Hu associated with limbic system 
lesions and lung cancer; 
• Anti-Ma2 (also called anti-Ta) ± Ma1 
associated alone with testicular cancers; 
• Anti-CV2/CRMP5 associated with 
SCLC or thymoma; 
• Antiamphysin antibodies; and 
• Anti-VGKC antibodies can exist with 
thymoma or non-paraneoplastic limbic 
encephalitis. 
 
The treatment of PLE is non-specific; 
however, spontaneous recovery has been 
described in 30-64% of cases depending on 
the presence/absence and type of antibod-
ies. Immunotherapy, in addition, is largely 
ineffective (Graus and Dalmau, 2007; 
Ghosh et al., 2007). Many cases were bene-
fiting from antitumor therapy and high dose 
steroids for approximately 5 days.  
Therefore, all efforts should be directed 
at identifying and treating the underlying 
tumor. If no tumor is established, the diag-
nostic and prognostic search should be re-
peated every 3-6 months for a period of 2-3 
years. As a prognosis, approximately 64 % 
of cases of patients without antibodies had 
partial neurological recovery (Graus and 
Dalmau, 2007). 
In getting back to our case, the patient 
took high dose of steroids and she received 
the treatment of her underlying breast can-
cer; she was clinically improving, at least 
partially, but the detection of neuronal anti-
bodies hasn’t been undertaken, which ne-
cessitates further analytical testing and fol-
low-up. 
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